摘要
甲状腺癌的发病率逐年上升,总体上治疗效果良好,但仍有一部分难治性甲状腺癌缺乏有效的治疗手段。随着甲状腺癌分子病理机制研究的不断进展,以激酶抑制剂为代表的分子靶向治疗逐步在晚期甲状腺癌治疗中得到越来越广泛的应用,为晚期甲状腺癌患者带来新的希望。
Although the incidence of thyroid cancer is increasing globally,most patients with thyroid cancer could get good prognosis after therapy.Undeniably,no effective treatment could improve the prognosis of some patients with advanced thyroid cancer evidently.With inereasing knowledge of the molecular pathogenesis of thyroid cancer,novel targeted therapies,led by kinase inhibitor,have been developed in therapy,which hold out hope of better health and longer life in terminal patients.
作者
陈万军
王之奇
王世军
Chen Wanjun;Wang Zhiqi;Wang Shijun(Department of Head and Neck Surgery,Shandong Cancer Hospital Affiliated to Shandong University, Shandong Cancer Hospital & Institute,Jinan 250117,China;Shandong Co-Innovation Center of Classic TCM Formula,Shandong University of Traditional Chinese Medicine,Jinan 250355,China;School of Basic Medical Sciences,Shandong University of Traditional Chinese Medicine,Jinan 250355,China)
出处
《国际耳鼻咽喉头颈外科杂志》
2019年第1期1-4,共4页
International Journal of Otolaryngology-Head and Neck Surgery
基金
山东省中医经典名方协同创新中心资助(2018KFY01).
关键词
甲状腺肿瘤
分子靶向治疗
Thyroid Neoplasms
Molecular Targeted Therapy
